A new approach to tackling non-small cell lung cancer (NSCLC) that is resistant to other treatments appears to be safe for patients. In an ongoing phase I/II clinical trial, people with advanced NSCLC without mutations in the EGFR gene, and who had not benefitted from previous therapies, were given a combination of erlotinib (Tarceva) and MLN8237 (Alisertib). Tarceva targets mutations in the EGFR gene, but may also be effective for patients without such mutations, especially when combined with another drug. While it is too early in the trial to determine whether the Tarceva-Alisertib combination is effective, the treatment produced minimal side effects, paving the way for more in-depth studies.